CSPC Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6,090	6,777	12,015	10,298	9,284
Short-Term Investments	4,283	2,360	1,750	4,268	2,024
Cash & Short-Term Investments	10,373	9,137	13,765	14,566	11,307
Cash Growth	13.52%	-33.62%	-5.50%	28.82%	21.38%
Accounts Receivable	8,694	9,542	9,712	6,736	6,508
Other Receivables	92.55	79.18	129.65	100.05	39.78
Receivables	8,787	9,621	9,841	6,836	6,549
Inventory	3,091	3,130	3,139	2,555	2,480
Total Current Assets	22,251	21,888	26,745	23,957	20,337
Property, Plant & Equipment	13,489	12,503	11,643	10,977	9,564
Long-Term Investments	7,109	6,271	4,596	3,720	3,323
Goodwill	234.9	234.9	234.9	234.9	149.98
Other Intangible Assets	2,658	2,518	2,146	1,872	425.87
Long-Term Deferred Tax Assets	211.51	250.3	186.78	113.03	43
Long-Term Deferred Charges	116.92	91.8	52.53	35.81	41.98
Other Long-Term Assets	628.05	632.23	678.51	859.31	857.51
Total Assets	46,698	44,389	46,282	41,770	34,742
Accounts Payable	3,409	2,988	2,889	2,206	1,770
Accrued Expenses	3,613	3,821	-	3,922	3,166
Short-Term Debt	307.72	364.2	441.27	145.64	-
Current Portion of Long-Term Debt	21	28	8.95	7.84	-
Current Portion of Leases	131.69	58.99	149.63	142.07	38.42
Current Income Taxes Payable	229.13	137.51	379.45	261.61	260.73
Current Unearned Revenue	896.2	538.05	494.9	940.5	645.75
Other Current Liabilities	1,570	1,697	5,820	1,333	1,346
Total Current Liabilities	10,178	9,634	10,183	8,958	7,226
Long-Term Debt	-	-	-	28.95	-
Long-Term Leases	180.69	56.14	107.06	258.04	55.62
Long-Term Unearned Revenue	1,414	407.81	340.53	270.92	250.2
Long-Term Deferred Tax Liabilities	374.86	424.73	574.84	611.99	381.48
Other Long-Term Liabilities	-	-	59.16	-	-
Total Liabilities	12,148	10,523	11,264	10,128	7,913
Common Stock	11,061	11,033	10,899	10,899	10,899
Additional Paid-In Capital	511.55	588.85	390.53	196.57	46.79
Retained Earnings	26,871	25,650	26,245	23,192	19,188
Treasury Stock	-752.85	-612.04	-316.21	-83.71	-85.6
Comprehensive Income & Other	-4,513	-4,394	-4,015	-4,006	-4,062
Total Common Equity	33,178	32,265	33,203	30,198	25,987
Minority Interest	1,372	1,602	1,815	1,444	841.56
Shareholders' Equity	34,550	33,866	35,018	31,642	26,828
Total Liabilities & Equity	46,698	44,389	46,282	41,770	34,742
Total Debt	641.11	507.33	706.9	582.54	94.04
Net Cash (Debt)	9,732	8,630	13,058	13,984	11,213
Net Cash Growth	12.77%	-33.91%	-6.62%	24.70%	24.61%
Net Cash Per Share	0.85	0.74	1.10	1.17	0.94
Filing Date Shares Outstanding	11,422	11,538	11,852	11,917	11,918
Total Common Shares Outstanding	11,422	11,538	11,852	11,917	11,918
Working Capital	12,073	12,254	16,562	14,999	13,110
Book Value Per Share	2.90	2.80	2.80	2.53	2.18
Tangible Book Value	30,285	29,512	30,822	28,090	25,411
Tangible Book Value Per Share	2.65	2.56	2.60	2.36	2.13
Buildings	5,955	5,565	5,389	4,639	4,135
Machinery	10,549	9,943	9,194	7,317	6,723
Construction In Progress	2,918	2,235	1,246	2,245	1,534

Source: S&P Global Market Intelligence. Standard template. Financial Sources.